GlassScriptPhysician profile
Lisa A Kelch
NPI 1669479093
$1,278.29
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $37.25 · 2021: $43.71 · 2022: $485 · 2023: $344 · 2024: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $339.21 | 2022-2024 | Azstarys |
| Glaxosmithkline, LLC. | $154.22 | 2019-2024 | Pediarix, Bexsero |
| Merck Sharp & Dohme LLC | $90.58 | 2022-2023 | Gardasil 9, Vaxneuvance, Vaxelis |
| Neos Therapeutics, LP | $88.80 | 2022-2023 | Adzenys Xr-Odt |
| Tris Pharma INC | $75.14 | 2019-2023 | Dyanavel Xr |
| Sanofi-Aventis U.S. LLC | $57.84 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $55.29 | 2021-2024 | Flumist Quadrivalent |
| Ultragenyx Pharmaceutical INC. | $53.16 | 2022-2023 | |
| Kaleo, INC. | $42.84 | 2019-2023 | Auvi-Q |
| Pfizer INC. | $42.35 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $41.54 | 2022-2023 | Qelbree |
| Seqirus USA INC | $38.26 | 2022-2023 | Flucelvax Quadrivalent |
| Sanofi Pasteur INC. | $35.23 | 2021-2022 | |
| Shire North American Group INC | $30.56 | 2019 | |
| Ironshore Pharmaceuticals INC. | $24.94 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $23.69 | 2019 | |
| Cranial Technologies, INC | $19.74 | 2019 | |
| Adlon Therapeutics L.P. | $17.48 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.14 | 2019 | |
| Sobi, INC | $17.03 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.25 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Kelch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.